Could taking breaks from skin cancer drug keep it working?
NCT ID NCT04806646
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests a new way of taking the drug sonidegib for people with advanced basal cell carcinoma that cannot be surgically removed. Instead of taking the drug continuously, patients who have already achieved a complete response will take it in cycles with breaks (14 days on/14 days off or 7 days on/21 days off). The goal is to see if this tailored schedule helps patients stay cancer-free for 12 months while reducing side effects and improving quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sonidegib (Odomzo)
What this could lead to
If successful, this could offer a way for patients with advanced BCC to maintain their response with fewer drug side effects by taking breaks from treatment.
What could go wrong
This is a small, early-phase trial with only 21 participants, so results may not apply to everyone. The tailored schedule might not work for all patients, and side effects are still possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BASAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asst Degli Spedali Civili Di Brescia
Brescia, Italy